Myocardial Infarction — Clinical Documentation Guide (2026)

🔍 Definition

Myocardial infarction (MI) is defined as acute myocardial injury with clinical evidence of acute myocardial ischemia, consistent with the Fourth Universal Definition of Myocardial Infarction (2018) jointly issued by the European Society of Cardiology (ESC), American College of Cardiology (ACC), American Heart Association (AHA), and World Heart Federation (WHF). The hallmark is detection of a rise and/or fall of cardiac troponin (cTn) with at least one value above the 99th percentile upper reference limit (URL), in the context of ischemic symptoms, new ECG changes, imaging evidence of new loss of viable myocardium, or intracoronary imaging identifying thrombus.

MI is broadly categorized into five types under the 4th Universal Definition. Type 1 MI results from spontaneous atherosclerotic plaque rupture, erosion, or fissuring with intraluminal thrombus formation in one or more coronary arteries, leading to decreased myocardial blood flow. Type 2 MI occurs secondary to a mismatch between myocardial oxygen supply and demand without coronary plaque rupture — for example, in the setting of sepsis, severe anemia, hypotension, or sustained tachyarrhythmia. Types 3 (sudden cardiac death), 4a/4b/4c (PCI-related), and 5 (CABG-related) represent procedure-related or fatal infarctions that lack post-procedural biomarker data.

Electrocardiographically, MI is classified as ST-elevation MI (STEMI) when persistent ST-segment elevation is present, reflecting complete coronary occlusion requiring immediate reperfusion therapy, or non-ST-elevation MI (NSTEMI), where the artery is partially occluded. The FY2026 ICD-10-CM classification fully reflects this clinical framework, with specific codes for STEMI by anatomical wall, NSTEMI, Type 2 MI, and subsequent infarctions occurring within 28 days.

🗂️ Alternative Terminology

Multiple lay and clinical terms are used interchangeably for myocardial infarction, which can create documentation ambiguity for coders and CDI specialists.

🩺 Signs & Symptoms

Classic presentation includes crushing, pressure-like substernal chest pain radiating to the left arm, jaw, or shoulder, often accompanied by diaphoresis, nausea, and dyspnea. However, atypical presentations are common, particularly in women, elderly patients, and diabetics, who may present with epigastric pain, fatigue, or syncope without classic chest pain.

• Chest pain / pressure: Onset usually at rest or with exertion; typically >20 minutes duration; not relieved by nitroglycerin
• Radiation: Left arm, jaw, neck, back, or right arm
• Diaphoresis: Cold sweat, pallor
• Dyspnea: Particularly in anterior STEMI with LV dysfunction
• Nausea/vomiting: More common in inferior MI (RCA distribution)
• Syncope or presyncope: Due to hemodynamic compromise or arrhythmia
• Palpitations: Ventricular ectopy, VT, VF common with acute ischemia
• Silent MI: Asymptomatic, detected only on ECG or imaging (common in diabetics)
• ECG findings: ST elevation (STEMI), ST depression/T-wave inversion (NSTEMI), new LBBB, pathological Q-waves
• Biomarkers: Elevated cardiac troponin I or T above 99th percentile URL; CK-MB elevation

🧭 Differential Diagnosis

Chest pain with troponin elevation requires systematic exclusion of the following conditions before assigning a myocardial infarction code.

📋 Clinical Indicators for Coders/CDI

Documentation must support the specific MI type and ECG classification to justify code assignment. The following indicators directly drive code selection and CC/MCC designation.

🦴 Anatomy & Pathophysiology

The coronary circulation consists of the left main coronary artery (LMCA), which bifurcates into the left anterior descending (LAD) and left circumflex (LCx) arteries, and the right coronary artery (RCA). In right-dominant anatomy (~85% of patients), the RCA supplies the posterior descending artery (PDA). The LAD supplies the anterior wall and apex; the LCx supplies the lateral wall; the RCA supplies the inferior wall and right ventricle.

Type 1 MI pathophysiology begins with vulnerable plaque rupture or erosion within a coronary artery. Exposure of subendothelial collagen triggers platelet aggregation and thrombin generation, forming an acute thrombus that partially or completely occludes the lumen. Complete occlusion typically produces STEMI; partial occlusion produces NSTEMI. Ischemia progresses from subendocardium outward (wavefront phenomenon), with irreversible necrosis beginning within 20–40 minutes of complete ischemia and completing within 4–6 hours. Reperfusion by PCI or thrombolytics within this window salvages at-risk myocardium.

Type 2 MI pathophysiology involves supply-demand mismatch without plaque rupture. Reduced oxygen supply (severe anemia, hypotension, respiratory failure, coronary spasm) or increased demand (sustained tachyarrhythmia, severe hypertension) exceeds myocardial oxygen delivery capacity in the setting of fixed or dynamic coronary stenoses. This mechanism accounts for an estimated 25–30% of all MI presentations and carries distinct management implications per the ACC's summary of the 4th Universal Definition.

Infarction consequences include myocyte necrosis, ventricular remodeling, reduced ejection fraction, susceptibility to arrhythmia (VT/VF in first 24 hours), mechanical complications (papillary muscle rupture, free wall rupture, VSD), and longer-term heart failure if significant myocardium is lost.

💊 Medication Impact / Treatment

Pharmacologic management directly affects clinical trajectory and should be documented specifically to support CDI accuracy regarding complications (e.g., bleeding from anticoagulation) and acuity.

• Antiplatelet therapy: Aspirin (325 mg load, 81 mg maintenance) + P2Y12 inhibitor (ticagrelor, clopidogrel, prasugrel) — dual antiplatelet therapy (DAPT) is standard for ACS per 2025 ACC/AHA ACS Guidelines. Duration: 12 months post-stent for most patients.
• Anticoagulation: Unfractionated heparin (UFH), low-molecular-weight heparin (enoxaparin), bivalirudin, or fondaparinux during acute phase. Bleeding complications should be specifically documented and coded.
• Thrombolytics: Alteplase, tenecteplase — indicated for STEMI when PCI not available within 120 minutes. Administration of tPA warrants Z92.82 (status post administration of tPA in a different facility within last 24 hours) when applicable.
• Beta-blockers: Metoprolol, carvedilol — reduce mortality, prevent remodeling. Contraindicated in acute decompensated HF or cardiogenic shock.
• ACE inhibitors / ARBs: Lisinopril, ramipril — indicated for all MI patients with LVEF ≤40%, hypertension, or diabetes.
• Statins: High-intensity statin (atorvastatin 80 mg, rosuvastatin 40 mg) initiated in all MI patients regardless of baseline LDL.
• Nitrates: Sublingual or IV nitroglycerin for ongoing ischemic pain; withhold in right ventricular infarction (inferior STEMI with RV involvement).
• Mineralocorticoid receptor antagonists: Eplerenone/spironolactone post-MI with LVEF ≤40% and HF or diabetes.
• GLP-1 receptor agonists / SGLT2 inhibitors: Added post-MI in patients with diabetes for secondary prevention per updated guidelines.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO CDG members.